Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Other material event · Financial statements
Mineralys Therapeutics, Inc.
11
Other material event
Jun 3, 2026
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
Mineralys Therapeutics, Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock RADNOR, PA, June 3, 2026 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other dise…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Mineralys Therapeutics, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
